MYQORZO is the Only Cardiac Myosin Inhibitor with Data in Its U.S. Label Comparing Its Effectiveness to the Beta Blocker Metoprolol SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) updating the … Continue reading "Cytokinetics Announces Prescribing Information for MYQORZO®…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.